Gilder Gagnon Howe & Co. LLC Acquires 35,009 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Gilder Gagnon Howe & Co. LLC lifted its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 12.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 326,349 shares of the company's stock after purchasing an additional 35,009 shares during the period. Gilder Gagnon Howe & Co. LLC owned 0.50% of Kymera Therapeutics worth $13,129,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in KYMR. Price T Rowe Associates Inc. MD boosted its holdings in shares of Kymera Therapeutics by 3.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,870,333 shares of the company's stock worth $276,395,000 after buying an additional 224,859 shares in the last quarter. Wellington Management Group LLP grew its holdings in Kymera Therapeutics by 14.9% in the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company's stock worth $213,514,000 after purchasing an additional 688,967 shares during the period. Avoro Capital Advisors LLC increased its stake in Kymera Therapeutics by 14.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock valued at $207,184,000 after purchasing an additional 650,000 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Kymera Therapeutics by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company's stock valued at $196,617,000 after purchasing an additional 133,546 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Kymera Therapeutics by 5.0% in the 4th quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company's stock valued at $44,484,000 after buying an additional 52,263 shares during the period.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR traded up $0.08 during trading on Tuesday, reaching $33.69. The company's stock had a trading volume of 398,607 shares, compared to its average volume of 556,263. The firm has a market cap of $2.19 billion, a price-to-earnings ratio of -14.40 and a beta of 2.22. Kymera Therapeutics, Inc. has a 12 month low of $19.45 and a 12 month high of $53.27. The firm has a 50 day moving average of $29.80 and a 200-day moving average of $38.46.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $7.39 million for the quarter, compared to analysts' expectations of $14.81 million. Equities research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

KYMR has been the subject of a number of research reports. Citigroup started coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $52.00 price objective for the company. Stephens restated an "overweight" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Finally, HC Wainwright raised their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $56.36.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the sale, the chief financial officer now owns 201,886 shares in the company, valued at $6,147,428.70. This represents a 3.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Ellen Chiniara sold 2,241 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $68,238.45. Following the sale, the insider now owns 80,085 shares in the company, valued at approximately $2,438,588.25. The trade was a 2.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,659 shares of company stock worth $324,567. Insiders own 15.82% of the company's stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.